Bloom Burton restated their hold rating on shares of Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) in a research note published on Monday, Zacks.com reports.

Cipher Pharmaceuticals stock opened at C$1.21 on Monday. The stock’s 50 day moving average is C$1.23 and its 200 day moving average is C$1.43. The company has a debt-to-equity ratio of 62.34, a current ratio of 1.06 and a quick ratio of 0.98. The firm has a market cap of $33.10 million and a P/E ratio of 18.06. Cipher Pharmaceuticals has a one year low of C$1.11 and a one year high of C$3.66.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company offers EPURIS (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; LIPOFEN (CIP-FENOFIBRATE), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; CONZIP/DURELA (CIP-TRAMADOL ER), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain; and Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne in patients.

Recommended Story: Are sell-side analysts objective?

Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.